4.6 Article

Pre-Existing Adenovirus Immunity Modifies a Complex Mixed Th1 and Th2 Cytokine Response to an Ad5/HIV-1 Vaccine Candidate in Humans

期刊

PLOS ONE
卷 6, 期 4, 页码 -

出版社

PUBLIC LIBRARY SCIENCE
DOI: 10.1371/journal.pone.0018526

关键词

-

资金

  1. Public Health Service [U01 AI068618]

向作者/读者索取更多资源

The results of the recent Step Study highlight a need to clarify the effects of pre-existing natural immunity to a vaccine vector on vaccine-induced T-cell responses. To investigate this interaction, we examined the relationship between preexisting Ad5 immunity and T-cell cytokine response profiles in healthy, HIV-uninfected recipients of MRKAd5 HIV-1 gag vaccine (HVTN 050, ClinicalTrials.gov #NCT00849732). Participants were grouped by baseline Ad5 neutralizing antibody titer as either Ad5-seronegative (titer <= 18; n = 36) or Ad5-seropositive (titer >200; n = 34). Samples from vaccine recipients were analyzed for immune responses to either HIV-1 Gag peptide pools or Ad5 empty vector using an ex vivo assay that measures thirty cytokines in the absence of long-term culture. The overall profiles of cytokine responses to Gag and Ad5 had similar combinations of induced Th1- and Th2-type cytokines, including IFN-gamma, IL-2, TNF-alpha, IP-10, IL-13, and IL-10, although the Ad5-specific responses were uniformly higher than the Gag-specific responses (p<0.0001 for 9 out of 11 significantly expressed analytes). At the peak response time point, PBMC from Ad5-seronegative vaccinees secreted significantly more IP-10 in response to Gag (p = 0.008), and significantly more IP-10 (p = 0.0009), IL-2 (p = 0.006) and IL-10 (p = 0.05) in response to Ad5 empty vector than PBMC from Ad5-seropositive vaccinees. Additionally, similar responses to the Ad5 vector prior to vaccination were observed in almost all subjects, regardless of Ad5 neutralizing antibody status, and the levels of secreted IFN-gamma, IL-10, IL-1Ra and GM-CSF were blunted following vaccination. The cytokine response profile of Gag-specific T cells mirrored the Ad5-specific response present in all subjects before vaccination, and included a number of Th1- and Th2-associated cytokines not routinely assessed in current vaccine trials, such as IP-10, IL-10, IL-13, and GM-CSF. Together, these results suggest that vector-specific humoral responses may reduce vaccine-induced T-cell responses by previously undetected mechanisms.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Immunology

Diversity of Antiviral IgG Effector Activities Observed in HIV-Infected and Vaccinated Subjects

Yunda Huang, Guido Ferrari, Galit Alter, Donald N. Forthal, John C. Kappes, George K. Lewis, J. Christopher Love, Bhavesh Borate, Linda Harris, Kelli Greene, Hongmei Gao, Tran B. Phan, Gary Landucci, Brittany A. Goods, Karen G. Dowell, Hao D. Cheng, Chris Bailey-Kellogg, David C. Montefiori, Margaret E. Ackerman

JOURNAL OF IMMUNOLOGY (2016)

Article Mathematical & Computational Biology

Power/sample size calculations for assessing correlates of risk in clinical efficacy trials

Peter B. Gilbert, Holly E. Janes, Yunda Huang

STATISTICS IN MEDICINE (2016)

Article Immunology

A case for preART-adjusted endpoints in HIV therapeutic vaccine trials

Yunda Huang, Lily Zhang, Darren Jolliffe, Arnt-Ove Hovden, Mats Okvist, Giuseppe Pantaleo, Maja A. Sommerfelt

VACCINE (2016)

Article Virology

Selection of HIV vaccine candidates for concurrent testing in an efficacy trial

Ying Huang, Carlos DiazGranados, Holly Janes, Yunda Huang, Allan C. deCamp, Barbara Metch, Shannon Grant, Brittany Sanchez, Sanjay Phogat, Marguerite Koutsoukos, Niranjan Kanesa-Thasan, Patricia Bourguignon, Alix Collard, Susan Buchbinder, Georgia D. Tomaras, Julie McElrath, Glenda Gray, James G. Kublin, Lawrence Corey, Peter B. Gilbert

CURRENT OPINION IN VIROLOGY (2016)

Article Immunology

A Systems Vaccinology Approach Reveals Temporal Transcriptomic Changes of Immune Responses to the Yellow Fever 17D Vaccine

Jue Hou, Shuhui Wang, Manxue Jia, Dan Li, Ying Liu, Zhengpeng Li, Hong Zhu, Huifang Xu, Meiping Sun, Li Lu, Zhinan Zhou, Hong Peng, Qichen Zhang, Shihong Fu, Guodong Liang, Lena Yao, Xuesong Yu, Lindsay N. Carpp, Yunda Huang, Julie McElrath, Steve Self, Yiming Shao

JOURNAL OF IMMUNOLOGY (2017)

Article Medicine, Research & Experimental

Population pharmacokinetics analysis of VRC01, an HIV-1 broadly neutralizing monoclonal antibody, in healthy adults

Yunda Huang, Lily Zhang, Julie Ledgerwood, Nicole Grunenberg, Robert Bailer, Abby Isaacs, Kelly Seaton, Kenneth H. Mayer, Edmund Capparelli, Larry Corey, Peter B. Gilbert

Article Immunology

Predictors of durable immune responses six months after the last vaccination in preventive HIV vaccine trials

Yunda Huang, Lily Zhang, Holly Janes, Nicole Frahm, Abby Isaacs, Jerome H. Kim, David Montefiori, M. Julie McElrath, Georgia D. Tomaras, Peter B. Gilbert

VACCINE (2017)

Article Multidisciplinary Sciences

Immunogenicity of a novel Clade B HIV-1 vaccine combination: Results of phase 1 randomized placebo controlled trial of an HIV-1 GM-CSF-expressing DNA prime with a modified vaccinia Ankara vaccine boost in healthy HIV-1 uninfected adults

Susan P. Buchbinder, Nicole A. Grunenberg, Brittany J. Sanchez, Kelly E. Seaton, Guido Ferrari, M. Anthony Moody, Nicole Frahm, David C. Montefiori, Christine M. Hay, Paul A. Goepfert, Lindsey R. Baden, Harriet L. Robinson, Xuesong Yu, Peter B. Gilbert, M. Juliana McElrath, Yunda Huang, Georgia D. Tomaras

PLOS ONE (2017)

Article Medicine, Research & Experimental

Robust antibody and cellular responses induced by DNA-only vaccination for HIV

Stephen C. De Rosa, Srilatha Edupuganti, Yunda Huang, Xue Han, Marnie Elizaga, Edith Swann, Laura Polakowski, Spyros A. Kalams, Michael C. Keefer, Janine Maenza, Yiwen Lu, Megan C. Wise, Jian Yan, Matthew P. Morrow, Amir S. Khan, Jean D. Boyer, Laurent Humeau, Scott White, Michael Pensiero, Niranjan Y. Sardesai, Mark L. Bagarazzi, David B. Weiner, Guido Ferrari, Georgia D. Tomaras, David C. Montefiori, Lawrence Corey, M. Juliana McElrath

JCI INSIGHT (2020)

Article Biotechnology & Applied Microbiology

Prediction of serum HIV-1 neutralization titers of VRC01 in HIV-uninfected Antibody Mediated Prevention (AMP) trial participants

Yunda Huang, Lily Zhang, Amanda Eaton, Nonhlanhla N. Mkhize, Lindsay N. Carpp, Erika Rudnicki, Allan DeCamp, Michal Juraska, April Randhawa, Adrian McDermott, Julie Ledgerwood, Philip Andrew, Shelly Karuna, Srilatha Edupuganti, Nyaradzo Mgodi, Myron Cohen, Lawrence Corey, John Mascola, Peter B. Gilbert, Lynn Morris, David C. Montefiori

Summary: The study evaluated the efficacy of VRC01 for HIV-1 prevention and used statistical methods to predict its neutralization ability against viruses. The pharmacokinetics/pharmacodynamics joint modeling approach showed the best predictive performance, while simpler methods 1 and 2 performed comparably for predicting ID80 titers.

HUMAN VACCINES & IMMUNOTHERAPEUTICS (2022)

Article Biochemical Research Methods

Optimizing clinical dosing of combination broadly neutralizing antibodies for HIV prevention

Bryan T. Mayer, Allan C. deCamp, Yunda Huang, Joshua T. Schiffer, Raphael Gottardo, Peter B. Gilbert, Daniel B. Reeves

Summary: Broadly neutralizing antibodies (bNAbs) are a promising drug for the prevention and treatment of HIV. However, due to differences in breadth, potency, and in vivo longevity, it is important to optimize the composition and dose ratio of combination bNAb therapies to enhance efficacy.

PLOS COMPUTATIONAL BIOLOGY (2022)

Article Biochemistry & Molecular Biology

Neutralization titer biomarker for antibody-mediated prevention of HIV-1 acquisition

Peter B. Gilbert, Yunda Huang, Allan C. deCamp, Shelly Karuna, Yuanyuan Zhang, Craig A. Magaret, Elena E. Giorgi, Bette Korber, Paul T. Edlefsen, Raabya Rossenkhan, Michal Juraska, Erika Rudnicki, Nidhi Kochar, Ying Huang, Lindsay N. Carpp, Dan H. Barouch, Nonhlanhla N. Mkhize, Tandile Hermanus, Prudence Kgagudi, Valerie Bekker, Haajira Kaldine, Rutendo E. Mapengo, Amanda Eaton, Elize Domin, Carley West, Wenhong Feng, Haili Tang, Kelly E. Seaton, Jack Heptinstall, Caroline Brackett, Kelvin Chiong, Georgia D. Tomaras, Philip Andrew, Bryan T. Mayer, Daniel B. Reeves, Magdalena E. Sobieszczyk, Nigel Garrett, Jorge Sanchez, Cynthia Gay, Joseph Makhema, Carolyn Williamson, James I. Mullins, John Hural, Myron S. Cohen, Lawrence Corey, David C. Montefiori, Lynn Morris

Summary: By integrating serum concentration and in vitro inhibitory concentration, the PT80 biomarker can guide the effective prevention of HIV-1 acquisition. The PT80 biomarker can be used to predict HIV-1 prevention efficacy and is proposed as a tool for evaluating bNAb regimens and candidate vaccines.

NATURE MEDICINE (2022)

Article Multidisciplinary Sciences

Immune correlates analysis of the PREVENT-19 COVID-19 vaccine efficacy clinical trial

Youyi Fong, Yunda Huang, David Benkeser, Lindsay N. Carpp, German Anez, Wayne Woo, Alice McGarry, Lisa M. Dunkle, Iksung Cho, Christopher R. Houchens, Karen Martins, Lakshmi Jayashankar, Flora Castellino, Christos J. Petropoulos, Andrew Leith, Deanne Haugaard, Bill Webb, Yiwen Lu, Chenchen Yu, Bhavesh Borate, Lars W. P. van der Laan, Nima S. Hejazi, April K. Randhawa, Michele P. Andrasik, James G. Kublin, Julia Hutter, Maryam Keshtkar-Jahromi, Tatiana H. Beresnev, Lawrence Corey, Kathleen M. Neuzil, Dean Follmann, Julie A. Ake, Cynthia L. Gay, Karen L. Kotloff, Richard A. Koup, Ruben O. Donis, Peter B. Gilbert

Summary: In the PREVENT-19 phase 3 trial, the NVX-CoV2373 vaccine's effectiveness against COVID-19 was assessed using markers such as spike IgG, RBD IgG, and nAb ID50. The study found that higher concentrations of these markers were associated with lower COVID-19 risk and higher vaccine efficacy. The results suggest that these markers could be used across different vaccine platforms to guide decision-making on vaccine approval and usage.

NATURE COMMUNICATIONS (2023)

Correction Multidisciplinary Sciences

Immune correlates analysis of the PREVENT-19 COVID-19 vaccine efficacy clinical trial (vol 14, 331, 2023)

Youyi Fong, Yunda Huang, David Benkeser, Lindsay N. Carpp, German Anez, Wayne Woo, Alice McGarry, Lisa M. Dunkle, Iksung Cho, Christopher R. Houchens, Karen Martins, Lakshmi Jayashankar, Flora Castellino, Christos J. Petropoulos, Andrew Leith, Deanne Haugaard, Bill Webb, Yiwen Lu, Chenchen Yu, Bhavesh Borate, Lars W. P. van der Laan, Nima S. Hejazi, April K. Randhawa, Michele P. Andrasik, James G. Kublin, Julia Hutter, Maryam Keshtkar-Jahromi, Tatiana H. Beresnev, Lawrence Corey, Kathleen M. Neuzil, Dean Follmann, Julie A. Ake, Cynthia L. Gay, Karen L. Kotloff, Richard A. Koup, Ruben O. Donis, Peter B. Gilbert

NATURE COMMUNICATIONS (2023)

Article Medicine, Research & Experimental

Rectal tissue and vaginal tissue from intravenous VRC01 recipients show protection against ex vivo HIV-1 challenge

Rena D. Astronomo, Maria P. Lemos, Sandeep R. Narpala, Julie Czartoski, Lamar Ballweber Fleming, Kelly E. Seaton, Madhu Prabhakaran, Yunda Huang, Yiwen Lu, Katharine Westerberg, Lily Zhang, Mary K. Gross, John Hural, Hong-Van Tieu, Lindsey R. Baden, Scott Hammer, Ian Frank, Christina Ochsenbauer, Nicole Grunenberg, Julie E. Ledgerwood, Kenneth Mayer, Georgia Tomaras, Adrian B. McDermott, M. Juliana McElrath

Summary: The study showed that VRC01 can distribute into the female genital and male rectal mucosa, effectively inhibiting HIV-1 infection, providing new insights into in vivo protective efficacy.

JOURNAL OF CLINICAL INVESTIGATION (2021)

暂无数据